Mednet Logo
HomePrimary Care
Primary Care

Primary Care

Physician perspectives on preventive care, chronic disease management, and evidence-based primary care practice.

Recent Discussions

Would you avoid combining JAK inhibitors with IVIG given the risk of thromboembolism?

3
4 Answers

Mednet Member
Mednet Member
Rheumatology · Johns Hopkins Medicine

The evidence for this is not very clear and limited. I think a honest discussion about the risk of JAKs and IVIG with the patient will be the most important; but as long as there is no clotting history or high risk of DVTs/PEs, and this is documented, and if a patient needs both medications to attai...

When would you treat mild anemia from low testosterone in an older male?

2 Answers

Mednet Member
Mednet Member
Hematology · Medical University of South Carolina

The primary indication for testosterone treatment is symptomatic hypogonadism and not anemia. Given the risk for adverse events in terms of erythrocytosis, cardiovascular events, and potential prostate diseases, the risk of providing testosterone for asymptomatic, mild anemia outweighs its benefits,...

How do you manage neurocognitive decline associated with chemotherapy (i.e. chemo brain)?

4
3 Answers

Mednet Member
Mednet Member
Medical Oncology · Stanford University Medical Center

I agree with @Dr. First Last's detailed response. Practically speaking, I would also add that it is important to listen and validate your patient's concerns and respond to their frustration and sense of loss. A diagnostic evaluation will not only help you and your patient discover or 'rule out' othe...

Is there any contraindication to the use of ezetimibe in patients with a history of statin-induced necrotizing myopathy?

3
5 Answers

Mednet Member
Mednet Member
Rheumatology · Mobile Medical Care Inc

These types of questions are always great to discuss. The reality is there is a risk-benefit ratio to be considered. On one hand, there is a concern for the need for lipid-lowering to prevent cardiovascular disease, and some situations are more pressing than others. A diabetic with a known cardiovas...

How do you manage the developmental and behavioral regression seen in Down Syndrome Disintegrative Disorder (DSDD)?

1 Answers

Mednet Member
Mednet Member
Neurology · Virtua Health

Thank you for this important question. One of the keys is to ensure that the change and regression being seen is DSDD or something else. Sometimes, this is confused with Alzheimer's seen in older individuals with Down syndrome. DSDD is seen in much younger people, late teens, and 20's as a more rapi...

How do you decide between using immediate-release versus long-acting lithium?

6
1 Answers

Mednet Member
Mednet Member
Psychiatry · University of Colorado

In general, long-acting (i.e., controlled release) lithium is thought to cause less nausea and other common side effects (like tremors) than IR formulations but has also been associated with higher rates of diarrhea due to differences in absorption. Another consideration may be the dose you are try...

Should systemic anticoagulation be considered for patients with a less than 1% atrial fibrillation burden on outpatient monitoring with an elevated CHADSVASc score and acceptable bleeding risk?

1
2 Answers

Mednet Member
Mednet Member
Cardiology · Weill Cornell Medical College of Cornell University

This is a recurrent question. My policy is to anticoagulate such patients. The cutoff for anticoagulation is still controversial though. I believe that any episodes lasting longer than 5 min deserve anticoagulation. Not so sure what to do with shorter episodes but my philosophy is that prevention of...

How have you incorporated new psoriasis therapies such as deucravacitinib and bimekizumab into your hierarchy of psoriasis treatments?

2
3 Answers

Mednet Member
Mednet Member
Dermatology · Icahn School of Medicine at Mount Sinai (Elmhurst)

I have had good success with both deucravacitinib and bimekizumab and these agents are two welcome additions to our psoriasis treatment arsenal. For deucravacitinib, ever since I included it in my list of options in treating psoriasis - as an aside, I used to skip over orals due to lack of efficacy ...

How do you counsel patients on the risks and benefits of an IL-23 agent versus an IL-17A or IL-17A/F agent?

5
2 Answers

Mednet Member
Mednet Member
Dermatology · Medical College of Wisconsin

Both IL-17 and IL-23 agents have demonstrated excellent efficacy for psoriasis. Choosing between them often comes down to access and insurance coverage.With that being said, considerations include: Side effect profile: The side effect profile for both IL-23 and IL-17 agents is similar, with the exc...

How soon after excising a keloid do you inject kenalog?

3
10 Answers

Mednet Member
Mednet Member
Dermatology · University of Colorado

When I possible, I prefer to shave and leave no suture behind. I inject with TAC at the time of the surgery. I wait a few weeks and then start topical imiquimod qohs x 6 weeks and have patients follow up then.